Pfizer stock heads into November 3 results with lower consensus
Published on 11/01/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors will watch next
- Pfizer is expected to publish third-quarter results before the market opens on Tuesday, November 3.
- Analysts see third-quarter revenue falling from the prior-year period as COVID product sales remain under pressure.
- The update will test whether newer medicines and the obesity pipeline can offset declines in Paxlovid and Comirnaty.
Pfizer is set to report third-quarter results before the market opens on Tuesday, November 3, 2026. The preview by Yahoo Finance, carrying analysis from 24/7 Wall St., puts consensus revenue at USD 15.88 billion, below USD 16.65 billion in the year-earlier quarter.
Pfizer stock traded at EUR 27.28 on Lang & Schwarz at 17:06 CET on Sunday, November 1, 2026. The real-time quote of Pfizer stock gives investors a weekend reference ahead of the report.
Growth must offset COVID pressure
The earnings preview says adjusted earnings per share are expected at USD 0.728, compared with USD 0.87 a year earlier. The lower bar reflects continued pressure on pandemic products and a roughly USD 0.10 charge linked to the Innovent transaction.
Pfizer's second-quarter adjusted earnings per share reached USD 0.77, above the USD 0.6822 consensus, while revenue came in at USD 15.03 billion against an estimate of USD 14.39 billion. Launched and acquired products grew 18 percent operationally, but Paxlovid sales fell 95 percent and Comirnaty sales declined 34 percent.
Pipeline milestones in focus
Investors are also watching the company's oncology and obesity programs. Pfizer said the ELREXFIO MagnetisMM-32 study achieved its primary progression-free-survival endpoint, with estimated 18-month progression-free survival of 68 percent in an interim analysis.
The preview also highlights berobenatide, which produced placebo-corrected weight loss of up to 12.3 percent in the VESPER-3 study. Pfizer plans 10 Phase III studies in 2026 and is targeting a first approval in 2028, making development timing a key part of the longer-term growth case.
Management's current full-year outlook calls for revenue of USD 60.5 billion to USD 62.5 billion and adjusted earnings per share of USD 2.80 to USD 3.00. The November 3 release will show whether the newer portfolio is progressing fast enough to absorb weaker COVID sales.
Broader sentiment will also matter as investors assess Pfizer alongside the S&P 500.
For further developments, see More news and analyses on Pfizer stock.
Pfizer Inc. stock profile
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Home exchange: NYSE
- Lang & Schwarz quote: EUR 27.28 on November 1, 2026, at 17:06 CET
- Next event: Third-quarter results expected before the market open on November 3, 2026
